Acasti Pharma Inc V.ACST

Primary Symbol: ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Over 200K on the bid, which is 1% of outstanding shares

<< Previous

Bullboard Posts

Next >>

Comment by flush777on Jan 05, 2022 1:56pm

246 Views

Post# 34286061

RE:Over 200K on the bid, which is 1% of outstanding shares

Now 131,900 at the bid of $1.86 ... I think this or these buyers are very hungry buyers ... Let the wolves feast and pick up all the low hanging fruit awaiting conference news... hopefully very very good!

<< Previous

Bullboard Posts

Next >>

Grid Battery Metals sets spin-off date for AC/DC Battery shares